Post-transplant hyperlipidaemia: Low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin

Journal of Internal Medicine

Volumn 242, Issue 6, 1997, Pages 483-490

  Gullestad, L ^a   Nordal, K P ^a   Forfang, K ^a   Ihlen, H ^a   Hostmark A ^b   Berg, K J ^a   Cheng, H ^c   Schwartz, M S ^c   Geiran, O ^a   Simonsen, S ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apolipoproteins; Cholesterol; Hyperlipidaemia; Lovastatin; Transplantation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN A; FIBRINOGEN; GLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PREDNISOLONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 6844260530     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.1997.tb00021.x     Document Type: Article

References (44)

1. Bieber CP, Hunt SA, Schwinn DA, Jamieson SA, Reitz BA, Oyer PE et al. Complications in long-term survivors of cardiac transplantation. Transplant Proc 1981; 13: 207-11.
2. Gao SZ, Johnsen D, Schroeder JS, Alderman EL, Billingham ME, Hunt S et al. Transplant coronary artery disease: histopathologic correlations with angiographic morphology. J Am Coll Cardiol 1985; 11: 153A.
3. Davies H, Verney G, English T. The coronary arteries of the transplanted human heart: studies of the development of disease based on serial angiography. lnt J Cardiol 1991; 32: 35-50.
4. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987; 19 (Suppl. 5): 19-25.
5. Johnson ML. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11: S124-32.
6. Farmer JA, Ballantyne CM, Frazier OF, Radovacevic B, PaytonRoss C, Patsch W et al. Lipoprotein (a) and apolipoprotein changes after cardiac transplantation. J Am Coll Cardiol 1991; 18: 926-30.
7. Rudas L, Plugfelder PW, McKenzie FN, Menkis AH, Novick RJ, Kostuk WJ. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. Am J Cardiol 1990; 66: 1135-8.
8. Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipedemia after renal transplantation: Natural history and pathophysiology. Ann Intern Med 1979; 91: 554-9.
9. Hess ML, Hastillo A, Mohanakumar T, Cowley MJ, Vetrovac G, Szenrtpetery S et al. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983; 68 (Suppl. II): II94-II101.
10. Ibels LS, Simons LA, King JO, Williams PF, Neale FC, Stewart JH. Studies on the nature and causes of hyperlipidemia in uremia, maintenance dialysis and renal transplantation. Q J Med 1975: 176: 601-14.
11. Brown G, Alberts JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
12. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. JAMA 1984; 251: 351-64.
13. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch lnt Med 1991; 151: 43-9.
14. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4 444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 344: 1383-9.
15. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang X et al. Effect of pravastatin on outcome after cardiac transplantation. N Engl J Med 1995; 333: 621-7.
16. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-8.
17. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-1707.
18. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987; 258: 1183-6.
19. Witztum JL, Steinberg D, Role of oxidized low density lipoprotein in atherogenesis. J Clin Ivest 1991; 88: 1785-92.
20. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary on the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation. and treatment of high blood cholesterol in adults (Adult treatment panel II). JAMA 1993; 269: 3015-23.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
22. Berg JE, Høstmark AT. Cardiovascular risk determination: discrepancy between total evaluation and two compound laboratory indices in Norway. J Epidemiol Community Health 1994; 48: 338-43.
23. Morris MJ, Gilbert JP, Hsieh JY, Matuszewski BK, Ramjit HG, Bayne WF. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biol Mass Spectrum 1993; 22: 1-8.
24. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 (Suppl. IV): IV281-IV283.
25. Kuo PC, Kirsenbaum JM, Gordon J, Laffel G, Young P, DiSesa VJ et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989; 64: 631-5.
26. Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman WH et al. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988; 85: 632-8.
27. Bilodeau M, Fitchett DH, Guerraty A, Sniderman AD, Dyslipoproteinemias after heart-lung transplantation: Potential relation to accelerated graft arteriosclerosis. J Heart Transplant 1989; 8: 454-9.
28. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C et al. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992; 19: 1315-21.
29. Becker DM, Markakis M, Sension M, Vitalis S, Baughman K, Swank R et al Prevalence of hyperlipidemia in heart transplant recipients. Transplantation 1987; 44: 323-5.
30. Stamler JS, Vaughan DE, Rudd A, Mudge GH, Kirsenbaum J. Young P et al Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 1988: 62: 1268-72.
31. Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements. Variations and practical utility. JAMA 1992: 267: 1652-60.
32. Keogh A, Simons L, Spratt P, Esmore D, Chang V, Hickie J et al. Hyperlipidemia after heart transplantation. J Heart Transplant 1988; 7: 171-5.
33. Gao SZ, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol 1988; 62: 876-81.
34. Butman SM. Hyperlipidemia after cardiac transplantation: Be aware and possibly of drug therapy for lowering of serum lipids. Am Heart J 1991; 121: 1585-90.
35. Corpier CL, Jones ÅH, Suki WN, Lederer ED, Quinones MA, Schmidt SW et al. Rhabdomyolysis and renal injury with lovastatin use. JAMA 1988; 260: 239-41.
36. Meiser BM, Wencke K, Wolf S, Devens Ch Seidel D, Hammer C et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993; 25: 2077-9.
37. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994; 89: 959-68.
38. Chancerelle Y, de Lorgeril M, Viret R, Chiron B, Dureau G, Renaud S et al. Increased lipid peroxidation in cyclosporintreated heart transplant recipients. Am J Cardiol 1991; 68: 813-6.
39. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988; 318: 46-7.
40. Smith PF, Eyelloth RS, Grossman SJ, Stubbs JJ, Schwartz MS, Germershausen JI et al. Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporine A: evaluation in a ral model. Eur Heart J 1992; 13 (Suppl. B): 2-6.
41. Cheung AK, DeVault GA Jr, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884-91.
42. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germhausen JI et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 12-18.
43. Aoyma Y, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fisher V et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 1989; 264: 10388-95.
44. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin. Arch Biochem Biophys 1991; 290: 355-61.